Matches in SemOpenAlex for { <https://semopenalex.org/work/W55142037> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W55142037 abstract "Objective: The objective of this selective EBM review is to determine whether or not ipilimumab is an effective treatment in patients diagnosed with metastatic melanoma. Study Design: Review of three English primary studies published between 2009 and 2010. Data Sources: Randomized, controlled, double-blind clinical studies comparing ipilimumab +/gp100 peptide to a placebo +/gp100. Studies were found using PubMed and Cochrane databases. Outcomes Measured: Each of the studies measured outcomes of disease progression and overall survival. Response rate to treatment was also measured in two studies. Measurement of these outcomes was achieved utilizing the following classifications systems: [TNM] categorization, & Kaplan-Meier product-limit method of determining survival rates. Results: In the Hodi et al. study the median overall survival was greater among patients receiving ipilimumab plus glycoprotein100 (gp100), as compared to patients receiving gp100 alone. In the Weber et al. study the median overall response rates were higher for those receiving ipilimumab 10 mg/kg alone, in comparison to ipilimumab 10 mg/kg with budesonide (blind). Subjects with more severe irAEs (immune related adverse events) experienced better disease control compared to those with less serious irAEs. A dose-dependent relationship was illustrated in the Wolchok et al. study; best overall response rate was notably higher for those receiving a higher dose of ipilimumab, opposed to a lower dose. Conclusion: The results of all three of the reviewed RCT’s and randomized double-blind studies demonstrated that ipilimumab shows activity in advanced melanoma. According to Hodi et al., ipilimumab may improve overall survival. The study done by Wolchock et al. provides evidence of a dose-dependent relationship on efficacy of ipilimumab, along with irAEs. In terms of safety, it was reported that most adverse events were manageable if not reversible with appropriate treatment, although serious & life-threatening effects were possible. Continued research is needed to determine the optimal dosing and regimen for reducing adverse effects and maximizing efficacy. Further research is desired, particularly at a dose of 10 mg/kg." @default.
- W55142037 created "2016-06-24" @default.
- W55142037 creator A5014511435 @default.
- W55142037 date "2012-01-01" @default.
- W55142037 modified "2023-09-24" @default.
- W55142037 title "Is Ipilimumab an Effective Treatment in Patients Diagnosed with Metastatic Melanoma" @default.
- W55142037 cites W2095826876 @default.
- W55142037 cites W2097995306 @default.
- W55142037 cites W2119198740 @default.
- W55142037 hasPublicationYear "2012" @default.
- W55142037 type Work @default.
- W55142037 sameAs 55142037 @default.
- W55142037 citedByCount "0" @default.
- W55142037 crossrefType "journal-article" @default.
- W55142037 hasAuthorship W55142037A5014511435 @default.
- W55142037 hasConcept C121608353 @default.
- W55142037 hasConcept C126322002 @default.
- W55142037 hasConcept C142724271 @default.
- W55142037 hasConcept C143998085 @default.
- W55142037 hasConcept C168563851 @default.
- W55142037 hasConcept C197934379 @default.
- W55142037 hasConcept C204787440 @default.
- W55142037 hasConcept C27081682 @default.
- W55142037 hasConcept C2777658100 @default.
- W55142037 hasConcept C2777701055 @default.
- W55142037 hasConcept C2781433595 @default.
- W55142037 hasConcept C502942594 @default.
- W55142037 hasConcept C535046627 @default.
- W55142037 hasConcept C71924100 @default.
- W55142037 hasConceptScore W55142037C121608353 @default.
- W55142037 hasConceptScore W55142037C126322002 @default.
- W55142037 hasConceptScore W55142037C142724271 @default.
- W55142037 hasConceptScore W55142037C143998085 @default.
- W55142037 hasConceptScore W55142037C168563851 @default.
- W55142037 hasConceptScore W55142037C197934379 @default.
- W55142037 hasConceptScore W55142037C204787440 @default.
- W55142037 hasConceptScore W55142037C27081682 @default.
- W55142037 hasConceptScore W55142037C2777658100 @default.
- W55142037 hasConceptScore W55142037C2777701055 @default.
- W55142037 hasConceptScore W55142037C2781433595 @default.
- W55142037 hasConceptScore W55142037C502942594 @default.
- W55142037 hasConceptScore W55142037C535046627 @default.
- W55142037 hasConceptScore W55142037C71924100 @default.
- W55142037 hasLocation W551420371 @default.
- W55142037 hasOpenAccess W55142037 @default.
- W55142037 hasPrimaryLocation W551420371 @default.
- W55142037 hasRelatedWork W1508871122 @default.
- W55142037 hasRelatedWork W1978192005 @default.
- W55142037 hasRelatedWork W1982086114 @default.
- W55142037 hasRelatedWork W2000289048 @default.
- W55142037 hasRelatedWork W2025901111 @default.
- W55142037 hasRelatedWork W2030410349 @default.
- W55142037 hasRelatedWork W2088165794 @default.
- W55142037 hasRelatedWork W2096178881 @default.
- W55142037 hasRelatedWork W2121071739 @default.
- W55142037 hasRelatedWork W2125316761 @default.
- W55142037 hasRelatedWork W2132197524 @default.
- W55142037 hasRelatedWork W2269614721 @default.
- W55142037 hasRelatedWork W2397559582 @default.
- W55142037 hasRelatedWork W2513285370 @default.
- W55142037 hasRelatedWork W2515516401 @default.
- W55142037 hasRelatedWork W2605588408 @default.
- W55142037 hasRelatedWork W2891595323 @default.
- W55142037 hasRelatedWork W2945531574 @default.
- W55142037 hasRelatedWork W2966780664 @default.
- W55142037 hasRelatedWork W3134949487 @default.
- W55142037 isParatext "false" @default.
- W55142037 isRetracted "false" @default.
- W55142037 magId "55142037" @default.
- W55142037 workType "article" @default.